164 related articles for article (PubMed ID: 33399071)
1. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
[TBL] [Abstract][Full Text] [Related]
2. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
4. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
[TBL] [Abstract][Full Text] [Related]
5. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
[TBL] [Abstract][Full Text] [Related]
6. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy.
Chen Y; Chen C; Peng H; Lin S; Pan J; Zheng H; Zong J; Lin C
Sci Rep; 2024 Feb; 14(1):3950. PubMed ID: 38366057
[TBL] [Abstract][Full Text] [Related]
8. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.
Liu GY; Li Z; Chen XX; Xia WX; Yao HR; Xiang YQ
Head Neck; 2023 Oct; 45(10):2571-2579. PubMed ID: 37554098
[TBL] [Abstract][Full Text] [Related]
9. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
[TBL] [Abstract][Full Text] [Related]
10. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
12. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.
Xu H; Lu L; Lu T; Xu Y; Zong J; Huang C; Lin F; Zheng Y; Lin C; Lin S; Qiu S; Pan J; Lin S; Guo Q
Head Neck; 2021 Sep; 43(9):2602-2610. PubMed ID: 33904617
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.
Yan W; Sun C; Ou X; Hu C
Cancer Imaging; 2023 Feb; 23(1):21. PubMed ID: 36829263
[TBL] [Abstract][Full Text] [Related]
14. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study.
Li WZ; Lv SH; Liu GY; Liang H; Guo X; Lv X; Liu KY; Qiang MY; Chen X; Gu SZ; Xie CQ; Xia WX; Xiang YQ
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):120-130. PubMed ID: 32853711
[TBL] [Abstract][Full Text] [Related]
15. M1 stage subdivisions based on
Qiu HZ; Zhang X; Liu SL; Sun XS; Mo YW; Lin HX; Lu ZJ; Guo J; Tang LQ; Mai HQ; Liu LT; Guo L
Ther Adv Med Oncol; 2022; 14():17588359221118785. PubMed ID: 35983026
[TBL] [Abstract][Full Text] [Related]
16. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
[TBL] [Abstract][Full Text] [Related]
17. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
18. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
19. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]